Mark Maxfield to Neoplasm Staging
This is a "connection" page, showing publications Mark Maxfield has written about Neoplasm Staging.
Connection Strength
0.146
-
Reddington H, Emmerick I, Diaz Collante J, Maini A, Kanzaria R, Crawford A, Phillips W, Maxfield M, Uy K, Lou F. Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer. PLoS One. 2026; 21(6):e0349231.
Score: 0.054
-
Diaz Collante J, Crawford A, Reddington H, Markel A, Epstein M, Gray C, Lou F, Phillips W, Maxfield M, Uy K, Emmerick I. National trends in lung cancer stage, treatment, and time to treatment initiation after a major healthcare disruption (NCDB 2014-2022). J Cancer Policy. 2026 Jun; 48:100724.
Score: 0.053
-
Emmerick ICM, Singh A, Powers M, Lou F, Lin P, Maxfield M, Uy K. Factors associated with diagnosis of stages I and II lung cancer: a multivariate analysis. Rev Saude Publica. 2021; 55:112.
Score: 0.040